Agennix AG
Agennix develops oral, topical, and other forms of cancer treatments. The company's primary candidate, Talactoferrin, is an oral therapy in the late stages of development that is targeted to treat non-small cell lung cancer, a common and slow-growing type of lung cancer. Its other clinical development-stage candidates include therapies to treat tumors and prostate cancer, as well as non-cancerous conditions such as sepsis and diabetic foot ulcers. Agennix, which has offices in Munich, Germany; Princeton, New Jersey; and Houston, Texas, was formed in 2009 from the merger of Germany-based GPC Biotech AG and US-based Agennix Inc.
Contact Details
Executives
Chairman
Christof Hettich
Interim CEO
Friedrich von Bohlen und Halbach